GHK-Cu will be voted on in a subsequent February 2027 meeting HHS has announced that GHK-Cu is expected to return to Category 1 (after being moved to Category 2 in September 2023), which would restore compounding access for injectable formulations. The dosing below draws from the per-component research and is reflected in the FDA review committee documents for each peptide, which aligns with PeptideFoxs previous research
Suggested Use: As a dietary supplement, take 1 capsule daily, with a meal
The compound's gastric-slowing effect peaks 90-120 minutes post-dose and persists for 6-8 hours, so alignment with meal timing is critical
Semaglutide and sermorelin act on very different systems one on appetite and blood-sugar regulation, the other on growth-hormone pathways which leads some people to ask about using them together
Titration context: study schedules include eligibility rules and monitoring plans
The right person means an eligible adult without contraindications no personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2), no serious hypersensitivity to the active ingredient, not pregnant or breastfeeding, no severe gastroparesis
